StageZero Life Sciences Ltd.
SZLSF · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 9/30/2023 | |
|---|---|---|---|---|
| Revenue | $500 | $390 | $520 | $745 |
| % Growth | 28.1% | -24.9% | -30.3% | – |
| Cost of Goods Sold | $569 | $382 | $239 | $577 |
| Gross Profit | -$70 | $8 | $281 | $168 |
| % Margin | -13.9% | 2% | 54.1% | 22.6% |
| R&D Expenses | $0 | $0 | $0 | $20 |
| G&A Expenses | $283 | $703 | $569 | $922 |
| SG&A Expenses | $283 | $703 | $596 | $909 |
| Sales & Mktg Exp. | $0 | $0 | $26 | -$13 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $283 | $703 | $596 | $929 |
| Operating Income | -$352 | -$695 | -$315 | -$761 |
| % Margin | -70.5% | -178.2% | -60.6% | -102% |
| Other Income/Exp. Net | -$47 | $46 | -$70 | -$61 |
| Pre-Tax Income | -$399 | -$649 | -$385 | -$822 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$399 | -$649 | -$385 | -$822 |
| % Margin | -79.9% | -166.5% | -74% | -110.2% |
| EPS | -0.003 | -0.005 | -0.003 | -0.007 |
| % Growth | 37.7% | -71% | 53.7% | – |
| EPS Diluted | -0.003 | -0.005 | -0.003 | -0.007 |
| Weighted Avg Shares Out | 123,533 | 123,533 | 123,553 | 123,533 |
| Weighted Avg Shares Out Dil | 123,533 | 123,533 | 123,553 | 123,533 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $47 | $53 | $41 | $27 |
| Depreciation & Amortization | $15 | $44 | $18 | $38 |
| EBITDA | -$337 | -$553 | -$326 | -$747 |
| % Margin | -67.4% | -141.7% | -62.7% | -100.2% |